PCOS (Polycystic Ovary Syndrome): History of Treatment Over Decades

The 1935 Starting Point: Stein and Leventhal

The modern concept of PCOS originates from a 1935 paper by Irving Stein Sr. And Michael Leventhal, who described seven women with amenorrhea, hirsutism, and bilaterally enlarged polycystic ovaries. Their original report defined the syndrome that would carry their names for the next four decades. Before that publication, clinicians had no unified framework for this cluster of signs.

The Original Case Series

Stein and Leventhal reported that bilateral ovarian wedge resection restored menstrual cycles in all seven patients, and five of seven subsequently conceived. The operation removed roughly half of each ovary. Results were dramatic by the standards of the era. The mechanism was not understood at the time, but the procedure's success established ovarian tissue as the central target of treatment for the next 30 years.

What Clinicians Thought Was Happening

Through the 1940s and 1950s, the prevailing model attributed PCOS solely to primary ovarian dysfunction. Androgen excess was recognized, but its adrenal versus ovarian origin was debated. Insulin resistance was not part of the picture at all. That conceptual gap would take another four decades to close. Early endocrinological reviews from the 1950s framed the condition as a structural ovarian problem requiring structural correction.

Surgical Era: Ovarian Wedge Resection (1935 to 1970s)

Bilateral ovarian wedge resection was the dominant treatment from 1935 through the early 1970s. Surgeons removed a triangular wedge of cortical tissue from each ovary under general anesthesia through an open laparotomy. Reported ovulation rates ranged from 80% to 90% in retrospective series, and pregnancy rates reached 50 to 60% in selected patients. A 1963 review in the American Journal of Obstetrics and Gynecology compiled outcomes across 187 women and confirmed the procedure's short-term efficacy.

Complications That Ended the Open Era

Despite good ovulation outcomes, open wedge resection carried two significant long-term risks. Pelvic adhesion rates reached 30 to 40% in some series, directly reducing fertility by causing tubal obstruction. Ovarian reserve could also be damaged by aggressive resection. These harms, combined with the arrival of clomiphene citrate in the mid-1960s, gradually shifted practice away from surgery as the first-line approach. A Cochrane review on surgical ovulation induction later confirmed that open wedge resection is no longer appropriate given available alternatives.

The Clomiphene Era Begins (1960s, 1980s)

Clomiphene citrate, a selective estrogen receptor modulator, was approved by the FDA in 1967 and rapidly became the first-line ovulation induction agent for anovulatory PCOS. It blocks hypothalamic estrogen receptors, increases gonadotropin secretion, and stimulates follicular development. Ovulation rates of 70 to 85% per cycle were reported, with cumulative six-cycle pregnancy rates near 40 to 50% in carefully selected patients. A landmark paper in Fertility and Sterility established the dose-response relationship: 50 mg daily for five days was the starting dose, with escalation to 150 mg if needed.

Anti-Estrogen Limitations

Clomiphene's anti-estrogenic effects on the endometrium and cervical mucus reduced implantation rates even when ovulation was achieved. The peripheral anti-estrogen effect created a paradox: ovulation occurred but conditions for conception were suboptimal. This limitation drove research into alternative ovulation induction agents throughout the 1980s. Research published in the Journal of Clinical Endocrinology and Metabolism documented endometrial thinning as a consistent finding with higher clomiphene doses.

Gonadotropin Therapy as Adjunct

For clomiphene-resistant patients (defined as failure to ovulate after 150 mg daily), injectable gonadotropins became available through the 1970s. Human menopausal gonadotropin (hMG) and later recombinant FSH could induce ovulation in most clomiphene-resistant cases. However, multiple pregnancy rates of 20 to 25% and ovarian hyperstimulation syndrome (OHSS) rates up to 10% were serious drawbacks. Studies in the European Journal of Endocrinology confirmed that PCOS patients face higher OHSS risk than normogonadotropic anovulatory women due to higher antral follicle counts and androgen-driven follicle recruitment.

The Metabolic Turn: Recognizing Insulin Resistance (1980s, 1990s)

The most conceptually important shift in PCOS understanding came in 1980, when Burghen and colleagues published evidence that women with PCOS had hyperinsulinemia independent of obesity. That 1980 paper in the Journal of Clinical Endocrinology and Metabolism demonstrated that fasting insulin levels correlated with androgen concentrations, implying that insulin itself drove excess androgen production in the ovarian theca cells.

What Insulin Resistance Means for Treatment

The insulin-resistance model reframed PCOS as a systemic metabolic disorder, not just a reproductive one. It predicted that lowering insulin should reduce androgen levels and potentially restore ovulation. That prediction was testable with drugs already in clinical use for type 2 diabetes.

Metformin Enters PCOS Practice

By 1994, the first controlled trial of metformin in PCOS was published. Velazquez et al. In Metabolism showed that metformin 1,500 mg per day for eight weeks reduced fasting insulin by 35%, testosterone by 40%, and restored regular menses in 9 of 11 hyperandrogenic anovulatory women. This single small trial ignited a decade of research. The FDA has never approved metformin specifically for PCOS, but its off-label use spread rapidly through the 1990s based on mechanistic plausibility and positive early data. The FDA metformin label covers type 2 diabetes and prediabetes only.

Laparoscopic Ovarian Drilling (1980s, Present)

Laparoscopic ovarian drilling (LOD) replaced open wedge resection in the 1980s. Gynecologists used electrocautery or laser to create 4 to 10 punctures per ovary, each 3 mm wide and 3 mm deep, under laparoscopic guidance. The procedure achieves monofollicular ovulation without gonadotropins, reducing multiple pregnancy risk substantially. A randomized trial published in Human Reproduction compared LOD to gonadotropin therapy in clomiphene-resistant PCOS (N=168) and found equivalent six-month ovulation rates (54% versus 55%) with significantly fewer multiple pregnancies (1% versus 16%).

LOD Mechanism and Lasting Effects

The mechanism by which LOD restores ovulation remains partially speculative. Proposed explanations include reduced ovarian androgen secretion (lowering intra-ovarian androgen that blocks follicle maturation), decreased AMH levels, and improved gonadotropin sensitivity. Studies in the Journal of Clinical Endocrinology and Metabolism showed that LH and testosterone fell significantly within weeks of the procedure and remained lower for up to 12 months. LOD is still offered in 2025 for clomiphene-resistant, anovulatory PCOS without other infertility causes, though it is used less as letrozole has displaced it in many centers.

Combined Oral Contraceptives and Anti-Androgens (1960s, Present)

Combined oral contraceptives (COCs) became available in the early 1960s and were quickly recognized as effective for managing the menstrual irregularity and hyperandrogenism of PCOS. By suppressing LH, COCs reduce ovarian androgen production. The progestin component opposes endometrial hyperplasia caused by unopposed estrogen in anovulatory women. The Endocrine Society's 2013 PCOS guideline listed COCs as first-line pharmacological therapy for menstrual dysfunction and hirsutism in women not seeking pregnancy, a position retained in the 2023 update.

Spironolactone and Direct Androgen Blockade

Spironolactone, originally a mineralocorticoid antagonist developed in the 1950s, was repurposed as an anti-androgen for PCOS by the 1980s. At doses of 100 to 200 mg per day, it competitively blocks androgen receptors in the hair follicle and sebaceous gland. A 1982 study in the Journal of Clinical Endocrinology and Metabolism reported significant reduction in Ferriman-Gallwey hirsutism scores after 6 months of spironolactone. The drug requires concurrent contraception because of teratogenic risk (feminization of a male fetus), which has kept it as a second-line or add-on agent rather than universal first-line.

Cyproterone Acetate in Europe

Cyproterone acetate, an anti-androgenic progestin, became widely used in Europe and Canada from the 1970s onward as part of combined pills (notably Diane-35). It blocks androgen receptors directly and suppresses LH-driven ovarian androgen production simultaneously. Studies published in Clinical Endocrinology confirmed Ferriman-Gallwey score reductions of 30 to 40% over 12 months. Cyproterone acetate is not FDA-approved in the United States, limiting its use in American practice.

The Letrozole Breakthrough (2000s)

Letrozole, an aromatase inhibitor approved by the FDA for breast cancer in 1997, entered PCOS ovulation induction research in the early 2000s. By blocking aromatase, it prevents conversion of androgens to estrogens, removing the negative feedback on the hypothalamus and driving FSH release without the peripheral anti-estrogenic effects of clomiphene.

PPCOS II Trial Results

The key trial was PPCOS II, a multicenter randomized controlled trial (N=750) comparing letrozole 2.5 to 7.5 mg versus clomiphene 50 to 150 mg for 5 days per cycle across up to 5 cycles. Published in the New England England Journal of Medicine in 2014, PPCOS II showed that letrozole produced a significantly higher live birth rate than clomiphene (27.5% versus 19.1%, P<0.001) and higher ovulation rate (61.7% versus 48.3%) in women with PCOS and a BMI of 25 to 40. The 2023 International PCOS Guideline accordingly recommends letrozole as first-line ovulation induction ahead of clomiphene for most patients.

Metformin: Evidence Accumulates and Matures (2000s, 2010s)

Through the 2000s, larger randomized trials refined metformin's role. The PPCOS I trial (N=626), published in the New England Journal of Medicine in 2007, compared clomiphene alone, metformin alone, and the combination. Metformin alone produced a live birth rate of only 7.2% versus clomiphene's 22.5%, establishing that metformin is not a reliable ovulation induction monotherapy. The combination offered no significant advantage over clomiphene alone for live birth.

Where Metformin Still Fits

Despite losing the live-birth comparison, metformin retained a role in PCOS management. The 2023 International Evidence-Based PCOS Guideline recommends metformin for metabolic features (insulin resistance, impaired glucose tolerance, dyslipidemia) and as an adjunct to letrozole or clomiphene when those agents alone have failed. Typical doses in PCOS practice range from 1,000 to 2,000 mg per day extended-release to minimize gastrointestinal side effects. The guideline explicitly states: "Metformin improves menstrual irregularity, insulin resistance, and metabolic profiles but has limited efficacy as a sole ovulation induction agent."

Inositol Supplementation (2000s, Present)

Myo-inositol and D-chiro-inositol emerged as research targets after the discovery that inositol phosphoglycans serve as second messengers for insulin signaling. Women with PCOS have reduced ovarian D-chiro-inositol and impaired conversion of myo-inositol to D-chiro-inositol. A randomized trial in Gynecological Endocrinology demonstrated that myo-inositol 4 g per day for 14 weeks restored ovulation in 72% of previously anovulatory PCOS patients versus 52% with placebo. Inositol is sold as a supplement rather than an approved pharmaceutical, which limits regulatory oversight and standardization of formulations, but its low side-effect profile has made it popular as an adjunct. A 2021 meta-analysis in Nutrients pooling 14 trials found inositol supplementation significantly reduced fasting insulin (weighted mean difference: -2.35 mIU/L) and testosterone compared to placebo.

GLP-1 Receptor Agonists: The Current Frontier (2010s, 2025)

GLP-1 receptor agonists, developed initially for type 2 diabetes, have generated significant interest in PCOS over the past decade because of their effects on weight, insulin sensitivity, and potentially direct ovarian function. Liraglutide 1.2 to 1.8 mg and semaglutide 0.5 to 2.4 mg are the most studied agents. A 2022 randomized trial in eClinicalMedicine comparing liraglutide 1.8 mg to placebo in overweight PCOS patients (N=72) found that liraglutide produced 5.2% greater weight loss, reduced free androgen index by 22%, and restored regular menstrual cycles in 54% of participants over 26 weeks.

Semaglutide Data in PCOS

Semaglutide data in PCOS-specific populations remain largely from observational studies and small trials as of mid-2025, though the STEP-1 trial (N=1,961), published in the New England Journal of Medicine in 2021, showed 14.9% mean weight loss at 68 weeks with semaglutide 2.4 mg versus 2.4% placebo in adults with obesity. Because excess weight worsens PCOS severity, that degree of weight reduction translates clinically into improved ovulation, reduced androgens, and better metabolic markers in PCOS patients who are overweight or obese. Dedicated semaglutide PCOS trials are ongoing (NCT05584553 on ClinicalTrials.gov).

Position in Current Guidelines

The 2023 International Evidence-Based PCOS Guideline does not yet list GLP-1 agonists as a standard recommendation due to limited PCOS-specific randomized data at time of publication. The guideline states that GLP-1 agonists "may be considered in PCOS patients with obesity and metabolic comorbidities when other lifestyle and pharmacological strategies have been insufficient," reflecting cautious endorsement rather than a firm directive. This positioning will likely shift as dedicated trial data accrue through 2025 and 2026.

The 2023 International PCOS Guideline: Current Standard of Care

The 2023 International Evidence-Based PCOS Guideline, developed by a consortium including the Endocrine Society, the American Society for Reproductive Medicine (ASRM), and the European Society of Human Reproduction and Embryology (ESHRE), is the most comprehensive synthesis to date. Published in the Journal of Clinical Endocrinology and Metabolism, it covers diagnosis, lifestyle, pharmacological therapy, reproductive management, and psychological health across 254 evidence-based recommendations.

Key Guideline Shifts From Prior Versions

Several positions in the 2023 guideline represent genuine changes from the 2018 version:

• Letrozole is recommended over clomiphene as first-line ovulation induction for most anovulatory PCOS patients seeking pregnancy.
• Combined oral contraceptives remain first-line for symptom management in those not pursuing pregnancy, but the guideline cautions that the choice of progestin matters for metabolic risk.
• Lifestyle intervention (diet and exercise achieving 5 to 10% weight loss in those with overweight or obesity) is assigned the highest evidence grade for improving ovulation, menstrual regularity, and metabolic features.
• Psychological health screening for depression and anxiety is explicitly recommended at diagnosis and follow-up, reflecting data showing PCOS patients have roughly a 3-fold higher prevalence of depression than age-matched controls.

Diagnostic Criteria: Rotterdam 2003 Still Governs

The Rotterdam 2003 consensus criteria require two of three features: oligo- or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound (12 or more follicles 2 to 9 mm per ovary, or ovarian volume greater than 10 mL). The original Rotterdam consensus paper established this framework, and the 2023 guideline updated the follicle threshold to 20 or more follicles per ovary using modern high-frequency ultrasound transducers, acknowledging equipment advances since 2003. The updated threshold paper is in Human Reproduction.

Lifestyle and Behavioral Therapy: Consistent Evidence Across Eras

Across every decade of PCOS treatment history, lifestyle modification has appeared as supportive therapy. The evidence base has grown substantially. A Cochrane review of lifestyle interventions in PCOS (32 randomized trials, N=1,450) found that structured exercise and dietary modification improved BMI, fasting insulin, free androgen index, and menstrual frequency compared to no intervention, though effect sizes varied by intervention intensity. A 5% reduction in body weight in overweight PCOS patients can restore spontaneous ovulation in up to 55 to 60% of women in some series. The Endocrine Society guideline on obesity in PCOS grades lifestyle intervention as first-line before pharmacological therapy.

Dietary Approaches Studied

No single dietary pattern has emerged as definitively superior. Low-glycemic-index diets, Mediterranean-style diets, and calorie-restricted balanced diets have all shown benefit in reducing insulin resistance and androgen excess compared to usual diet in randomized trials. A 2017 systematic review in Obesity Reviews found no statistically significant difference in hormonal outcomes between low-GI and conventional diets when total caloric reduction was equivalent, suggesting total energy deficit may matter more than macronutrient composition.

Androgen-Mapping: Measuring What Matters

Consistent biochemical monitoring has improved treatment decisions across the decades. Total testosterone, free testosterone (or calculated free testosterone using sex-hormone binding globulin), DHEA-S, and LH/FSH ratio are standard measurements. The Endocrine Society's position on androgen assays from 2010 emphasized that total testosterone by mass spectrometry is more reliable than immunoassay methods at low concentrations typical of female patients, a recommendation that remains relevant because many laboratories still use immunoassay platforms that overestimate or underestimate values at low ranges.

Long-Term Cardiometabolic Risk: A Treatment Horizon That Matters

PCOS is associated with a substantially elevated lifetime cardiometabolic risk profile. Women with PCOS have a 2-fold higher risk of developing type 2 diabetes, as confirmed in a large meta-analysis in Diabetes Care (N=4,509, pooled OR 2.87, 95% CI 1.93 to 4.26). Cardiovascular risk markers including CRP, intima-media thickness, and dyslipidemia are elevated even in lean PCOS patients. A 2011 study in the Journal of Clinical Endocrinology and Metabolism found that lean PCOS women had significantly higher carotid intima-media thickness than BMI-matched controls, independent of glucose tolerance status.

This long-term risk profile means that treatment decisions made at diagnosis in a 22-year-old patient may have consequences that extend 30 to 40 years. The historical focus on reproductive endpoints has progressively broadened to include cardiometabolic monitoring as a standard of care component throughout a patient's life. The 2023 International PCOS Guideline recommends screening for glucose abnormalities every 1 to 3 years depending on risk factors, and cardiovascular risk factor assessment at diagnosis and periodically thereafter.

From Wedge Resection to Semaglutide: A Treatment Timeline

The 90-year arc of PCOS treatment reflects how mechanistic understanding drives therapeutic change. Each decade's dominant therapy grew from the decade's best model of pathophysiology:

• 1935 to 1960s: Ovaries as structural targets, corrected surgically.
• 1967 to 1980s: Hypothalamic-pituitary axis as the lever, manipulated with clomiphene.
• 1980s, 1990s: Insulin resistance identified, metformin introduced off-label.
• 1990s, 2000s: Anti-androgens formalized, laparoscopic drilling refines surgery.
• 2000s, 2010s: Letrozole established as superior to clomiphene, metformin's role clarified.
• 2010s, 2025: GLP-1 agonists offer weight loss with potential direct ovarian effects, inositol gains mechanistic support.

Each shift required a willingness to discard the previous framework when new data contradicted it. The PPCOS II trial replaced clinical consensus that clomiphene was optimal with a level I evidence base for letrozole. That is the model for how future therapies, including GLP-1 agonists and potentially kisspeptin analogs, will be evaluated.